TSLP and asthma: Tezepelumab is an anti-TSLP human monoclonal antibody that reduced exacerbation rates, increased lung function, and improved asthma control and quality of life in RCTs (Corren et al., 2021b; Menzies-Gow et al., 2021; Corren et al., 2023).